Genetic investigation of Nordic patients with complement-mediated kidney diseases

被引:4
作者
Rydberg, Viktor [1 ]
Aradottir, Sigridur Sunna [1 ]
Kristoffersson, Ann-Charlotte [1 ]
Svitacheva, Naila [1 ]
Karpman, Diana [1 ]
机构
[1] Lund Univ, Dept Pediat, Clin Sci Lund, Lund, Sweden
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
瑞典研究理事会;
关键词
complement; atypical hemolytic uremic syndrome; C3; glomerulopathy; membranoproliferative glomerulonephritis; genes; HEMOLYTIC-UREMIC SYNDROME; FACTOR-H MUTATIONS; COFACTOR PROTEIN CD46; FACTOR-I; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; FUNCTIONAL-CHARACTERIZATION; C3; GLOMERULOPATHY; VARIANTS; HUS; ACTIVATION;
D O I
10.3389/fimmu.2023.1254759
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Complement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) may be associated with rare genetic variants. Here we describe gene variants in the Swedish and Norwegian populations.Methods Patients with these diagnoses (N=141) were referred for genetic screening. Sanger or next-generation sequencing were performed to identify genetic variants in 16 genes associated with these conditions. Nonsynonymous genetic variants are described when they have a minor allele frequency of <1% or were previously reported as being disease-associated.Results In patients with aHUS (n=94, one also had IC-MPGN) 68 different genetic variants or deletions were identified in 60 patients, of which 18 were novel. Thirty-two patients had more than one genetic variant. In patients with C3G (n=40) 29 genetic variants, deletions or duplications were identified in 15 patients, of which 9 were novel. Eight patients had more than one variant. In patients with IC-MPGN (n=7) five genetic variants were identified in five patients. Factor H variants were the most frequent in aHUS and C3 variants in C3G. Seventeen variants occurred in more than one condition.Conclusion Genetic screening of patients with aHUS, C3G and IC-MPGN is of paramount importance for diagnostics and treatment. In this study, we describe genetic assessment of Nordic patients in which 26 novel variants were found.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Mechanisms of Complement-Mediated Damage in Hematological Disorders
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    SEMINARS IN HEMATOLOGY, 2018, 55 (03) : 118 - 123
  • [32] Urinary complement biomarkers in immune-mediated kidney diseases
    Kesarwani, Vartika
    Bukhari, Muhammad Hamza
    Kahlenberg, J. Michelle
    Wang, Shudan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [33] Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation
    Obata, Shota
    Hullekes, Frank
    V. Riella, Leonardo
    Cravedi, Paolo
    TRANSPLANTATION REVIEWS, 2024, 38 (03)
  • [34] C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease
    Heiderscheit, Amanda K.
    Hauer, Jill J.
    Smith, Richard J. H.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS, 2022, 190 (03) : 344 - 357
  • [35] Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies
    Lionaki, Sophia
    Gakiopoulou, Hara
    Boletis, John N.
    APMIS, 2016, 124 (09) : 725 - 735
  • [36] Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome
    Dineke Westra
    Elena B. Volokhina
    Renate G. van der Molen
    Thea J. A. M. van der Velden
    Annelies Jeronimus-Klaasen
    Joop Goertz
    Valentina Gracchi
    Eiske M. Dorresteijn
    Antonia H. M. Bouts
    Mandy G. Keijzer-Veen
    Joanna A. E. van Wijk
    Jaap A. Bakker
    Anja Roos
    Lambert P. van den Heuvel
    Nicole C. A. J. van de Kar
    Pediatric Nephrology, 2017, 32 : 297 - 309
  • [37] Small-molecule factor B inhibitor for the treatment of complement-mediated diseases
    Schubart, Anna
    Anderson, Karen
    Mainolfi, Nello
    Sellner, Holger
    Ehara, Takeru
    Adams, Christopher M.
    Mac Sweeney, Aengus
    Liao, Sha-Mei
    Crowley, Maura
    Littlewood-Evans, Amanda
    Sarret, Sophie
    Wieczorek, Grazyna
    Perrot, Ludovic
    Dubost, Valerie
    Flandre, Thierry
    Zhang, Yuzhou
    Smith, Richard J. H.
    Risitano, Antonio M.
    Karki, Rajeshri G.
    Zhang, Chun
    Valeur, Eric
    Sirockin, Finton
    Gerhartz, Bernd
    Erbel, Paulus
    Hughes, Nicola
    Smith, Thomas M.
    Cumin, Frederic
    Argikar, Upendra A.
    Haraldsson, Boerje
    Mogi, Muneto
    Sedrani, Richard
    Wiesmann, Christian
    Jaffee, Bruce
    Maibaum, Juergen
    Flohr, Stefanie
    Harrison, Richard
    Eder, Joerg
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (16) : 7926 - 7931
  • [39] Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases
    Dixon, Bradley P.
    Greenbaum, Larry A.
    Huang, Liwei
    Rajan, Sandeep
    Ke, Chunlei
    Zhang, Yiwei
    Li, Li
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (11): : 2284 - 2293
  • [40] Expansion of Anticomplement Therapy Indications from Rare Genetic Disorders to Common Kidney Diseases
    Miwa, Takashi
    Sato, Sayaka
    Golla, Madhu
    Song, Wen-Chao
    ANNUAL REVIEW OF MEDICINE, 2024, 75 : 189 - 204